The performance of the European Society of Cardiology (ESC) algorithm, ESC 0/1-h, in ruling out acute myocardial infarction (AMI) without ST-elevation was comparable in patients with and without diabetes mellitus (DM), according to a study published in Diabetes Care. The ESC 0/1-h and 0/3-h algorithms are used to diagnose patients with suspected acute non-ST-elevation myocardial infarction (NSTEMI) Continue reading →

OBJECTIVE: Acutemyocardial infarction(AMI) carries increased risk of mortality and excess costs. Disease Management Programs (DMPs) providing guideline-recommended care for chronic diseases seem an intuitively appealing way to enhance health outcomes for patients with chronic conditions such as AMI Continue reading →

Background In survivors of acute ST-segment-elevationmyocardial infarction(STEMI), increased aortic stiffness is associated with worse clinical outcome; however, the underlying pathomechanisms are incompletely understood. We aimed to investigate associations between aortic stiffness and infarct healing using comprehensive cardiac magnetic resonance imaging in patients with acute STEMI. This was a prospective observational study including 103 consecutive STEMI patients treated with primary percutaneous coronary intervention. Continue reading →

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Apabetalone is a first-in-class, small molecule, bromodomain and extraterminal domain (BET) inhibitor that selectively targets bromodomain 2 (BD2) at the transcription level Continue reading →

Heart attacks often have a classic roster of symptoms: chest pain, shortness of breath, and the sensation of something heavy on the chest. But not always. Silent heart attacks, more formally known as a silent myocardial infarction (SMI), are "silent" because symptoms are so mild that people often do not realize they occurred Continue reading →

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Apabetalone is a first-in-class, small molecule, bromodomain and extraterminal domain (BET) inhibitor that selectively targets bromodomain 2 (BD2) at the transcription level Continue reading →

Jens Ellingsen, 1 Gunnar Johansson, 2 Kjell Larsson, 3 Karin Lisspers, 2 Andrei Malinovschi, 4 Bjrn Stllberg, 2 Marcus Thuresson, 5 Christer Janson 1 1Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden; 2Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden; 3Integrative Toxicology, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 4Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden; 5Statisticon AB, Uppsala, Sweden Correspondence: Jens Ellingsen Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Akademiska Sjukhuset, Uppsala SE-751 85, Sweden Tel +46 18 611 13 93 Fax +46 18 611 02 28 Email jens.ellingsen@medsci.uu.se Background: Life expectancy is significantly shorter for patients with chronic obstructive pulmonary disease (COPD) than the general population. Concurrent diseases are known to infer an increased mortality risk in those with COPD, but the effects of pharmacological treatments on survival are less established. Continue reading →